GLTO Insider Trading
Insider Ownership Percentage: 10.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $11,961.66
Galecto Share Price & Price History
Current Price: $22.89
Price Change: ▲ Price Increase of +0.75 (3.39%)
As of 12/4/2025 05:00 PM ET
Galecto Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/3/2025 | Hans T. Schambye | CEO | Sell | 735 | $3.38 | $2,484.30 | 4,022 | |
| 7/3/2025 | Lori Firmani | CFO | Sell | 147 | $3.39 | $498.33 | 692 | |
| 1/3/2025 | Hans T. Schambye | CEO | Sell | 1,341 | $5.60 | $7,509.60 | 3,397 | |
| 1/3/2025 | Lori Firmani | CFO | Sell | 261 | $5.63 | $1,469.43 | 465 | |
| 7/31/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 8,376 | $75.00 | $628,200.00 | 5,421 | |
| 7/25/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 1,568 | $73.00 | $114,464.00 | 6,486 | |
| 7/13/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 7,788 | $60.00 | $467,280.00 | 6,798 | |
| 4/17/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 523 | $49.25 | $25,757.75 | 7,190 | |
| 4/14/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 1,657 | $46.50 | $77,050.50 | 7,216 | |
| 4/12/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 94 | $45.25 | $4,253.50 | 7,328 | |
| 4/10/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 2,049 | $44.75 | $91,692.75 | 7,436 | |
| 4/5/2023 | Orbimed Advisors Llc | Major Shareholder | Sell | 3,718 | $54.50 | $202,631.00 | 7,484 | |
Galecto Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Connective Capital Management LLC | 26,956 | $100K | 0.1% | N/A | 2.027% |  |
| 11/17/2025 | Novo Holdings A S | 86,579 | $0.32M | 0.0% | -13.3% | 6.510% |  |
| 11/14/2025 | Virtu Financial LLC | 13,128 | $49K | 0.0% | N/A | 0.987% |  |
| 11/14/2025 | Two Sigma Investments LP | 20,296 | $76K | 0.0% | N/A | 1.526% |  |
| 2/17/2025 | Squarepoint Ops LLC | 12,701 | $59K | 0.0% | N/A | 0.962% |  |
| 2/13/2025 | Renaissance Technologies LLC | 15,044 | $70K | 0.0% | -29.6% | 1.140% |  |
| 10/24/2024 | Novo Holdings A S | 99,913 | $1.21M | 0.1% | -96.0% | 0.369% |  |
| 11/15/2023 | Laurion Capital Management LP | 88,580 | $64K | 0.0% | -53.5% | 0.327% |  |
| 8/8/2023 | Belvedere Trading LLC | 15,037 | $38K | 0.0% | N/A | 0.055% |  |
| 8/4/2023 | Simplex Trading LLC | 11,399 | $28K | 0.0% | +3,699.7% | 0.042% |  |
| 8/2/2023 | MAI Capital Management | 245,281 | $0.62M | 0.0% | -4.0% | 0.956% |  |
| 7/10/2023 | Trust Co. of Toledo NA OH | 22,432 | $57K | 0.0% | +86.9% | 0.087% |  |
| 5/10/2023 | MAI Capital Management | 255,453 | $0.51M | 0.0% | +9.5% | 0.995% |  |
| 2/9/2023 | MAI Capital Management | 233,283 | $0.27M | 0.0% | -31.2% | 0.912% |  |
| 9/16/2022 | Federated Hermes Inc. | 40,000 | $69K | 0.0% | +53.8% | 0.158% |  |
| 7/19/2022 | MAI Capital Management | 320,860 | $0.56M | 0.0% | N/A | 1.270% |  |
| 7/15/2022 | Marquette Asset Management LLC | 60,244 | $0.10M | 0.0% | +31.6% | 0.238% |  |
| 4/26/2022 | Marquette Asset Management LLC | 45,765 | $0.10M | 0.0% | +25.4% | 0.181% |  |
| 1/19/2022 | Marquette Asset Management LLC | 36,500 | $0.11M | 0.0% | +51.2% | 0.144% |  |
| 11/16/2021 | Janus Henderson Group PLC | 1,286,007 | $4.50M | 0.0% | -1.0% | 5.091% |  |
| 11/16/2021 | Migdal Insurance & Financial Holdings Ltd. | 10,400 | $37K | 0.0% | N/A | 0.041% |  |
| 11/16/2021 | Two Sigma Advisers LP | 243,500 | $0.87M | 0.0% | N/A | 0.964% |  |
| 11/16/2021 | Two Sigma Investments LP | 152,353 | $0.55M | 0.0% | N/A | 0.603% |  |
| 11/16/2021 | Laurion Capital Management LP | 194,852 | $0.70M | 0.0% | -6.1% | 0.771% |  |
| 11/12/2021 | Renaissance Technologies LLC | 102,900 | $0.37M | 0.0% | +159.2% | 0.407% |  |
| 10/12/2021 | Marquette Asset Management LLC | 24,135 | $87K | 0.0% | N/A | 0.096% |  |
Data available starting January 2016
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More on Galecto
Today's Range
Now: $22.89
52 Week Range
Now: $22.89
Volume
207,024 shs
Average Volume
3,389,384 shs
Market Capitalization
$30.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.4
Who are the company insiders with the largest holdings of Galecto?
Who are the major institutional investors of Galecto?
Which institutional investors are selling Galecto stock?
In the last quarter, GLTO stock was sold by these institutional investors:
- Novo Holdings A S
Within the previous year, company insiders that have sold Galecto company stock include:
- Hans T Schambye (CEO)
- Lori Firmani (CFO)
Learn More investors selling Galecto stock.
Which institutional investors are buying Galecto stock?
In the last quarter, GLTO stock was purchased by institutional investors including:
- Connective Capital Management LLC
- Two Sigma Investments LP
- Virtu Financial LLC